Sort
10,766 grants matching “checkpoint inhibitor”
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
$761,749Andrew Sikora · University Of Tx Md Anderson Can Ctr · U01 · FY2020 · DE
Personalized precision dosing of biologic therapies in oncology
$759,813Bradley T Messmer · Abreos Biosciences, Inc. · R44 · FY2017 · CA
Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors
$759,285James F Kronauge · Cytosite Biopharma, Inc. · R44 · FY2019 · CA
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
$759,203Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2025 · CA
The impact of sex and cell death on checkpoint inhibitor hepatotoxicity
$759,135Lily Dara · University Of Southern California · R01 · FY2025 · DK
Cancer immunotherapy
$758,271Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Mitotic roles of Nuclear Pore Complex (NPC) proteins
$757,763Mary C. Dasso · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2014 · HD
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
$756,968Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2021 · CA
Live cell reporters of genetic changes in stiff vs soft surroundings - Causes & Consequences
$756,522Dennis E. Discher · University Of Pennsylvania · U01 · FY2024 · CA
Mechanism and inhibition of SREBP-dependent cholesterol/lipid metabolism
$756,148Gerhard Wagner · Harvard Medical School · R01 · FY2015 · HL
Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
$755,970Dennis G. Moledina · Yale University · R01 · FY2024 · DK
Genetically Engineered Mouse Models to Study Melanoma Genesis and Progression
$755,852Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$755,852Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Applications of a robust, vector-free intracellular delivery platform for immune cells
$755,544Scott McNabb Loughhead · Sqz Biotechnologies Company, Inc. · R44 · FY2018 · GM
Identification of radiosensitizers for prostate cancer
$755,444Travis Stracker · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
$755,393Robbie G. Majzner · Dana-Farber Cancer Inst · U01 · FY2024 · CA
Understanding IDH mutant gliomas
$755,171Jing Wu · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Mechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell Carcinoma
$754,861Nicole Schmitt · National Institute On Deafness And Other Communication Disorders · ZIA · FY2016 · DC
Discovery of host genetic elements affecting response to immune checkpoint inhibitors
$754,511Edison Tak-Bun Liu · Jackson Laboratory · R01 · FY2025 · CA
Molecular, Cellular, and Tissue Characterization Unit
$752,398Joe W. Gray · Oregon Health & Science University · U2C · FY2022 · CA
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
$752,351James R. Heath · Institute For Systems Biology · U54 · FY2023 · CA
T cells in the aging brain
$752,242Anne Brunet · Stanford University · R01 · FY2021 · AG
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
$752,010Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR Phenotyping
$751,954Han Zhu · Stanford University · R01 · FY2024 · HL
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
$751,633Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2023 · CA